Anterior Uveitis with Posterior Synechia and Iris Atrophy Following Implantation of a Phakic Intraocular Lens.

PURPOSE: To describe a case with acute postoperative uveitis, posterior synechia and iris atrophy following iris-claw phakic intraocular lens (pIOL) implantation.
METHODS: A case report.
RESULTS: A 26-year-old man with high myopia had implantation of a -14.0 diopter, foldable, iris-claw Artiflex (model 401) anterior chamber pIOL (Ophtec B.V.) in both eyes. On the third postoperative day, the patient had significant postoperative inflammation in the left eye and received topical steroids and mydriatic eye drops. On the fifth postoperative day, the right eye had a round pupil and centered pIOL, but the left eye had an atrophic iris and dilated pupil with significant posterior synechias over the inferior half of the pupil. Despite intensive topical steroid application, the synechias remained one year after surgery.
CONCLUSION: Severe uveitis with posterior synechia can occur after iris-claw pIOL implantation. We hypothesized that excessive iris tissue enclavation in the pIOLs haptics and large iridotomies may be an associated factor.

Introduction

Phakic intraocular lenses (pIOLs) revolutionized refractive surgery and currently are an excellent option for high refractive errors not suitable for laser vision correction.1 A 6.2-mm corneal incision is essential for the phakic intraocular lens implantation due to the polymethyl-methacrylate (PMMA) material. Therefore, this technique can induce significant postoperative astigmatism. The surgically induced astigmatism (SIA) following iris-claw pIOLs was reduced through the development of the foldable versions (Artiflex, Ophtec BV, Groningen, The Netherlands/Veriflex, Johnson & Johnson Vision, Santa Ana, CAL, USA).2,3 These models of pIOL have PMMA haptics and a 6.0 mm foldable polysilicon optic and can be implanted through a 3.2 mm incision. In addition to induced astigmatism, other both early and late complications can occur after implantation of rigid and flexible models of iris-claw-type pIOLs.4–8 These complications include uveitis with anterior or posterior synechias, and pigment dispersion possibly related to the contact or closeness of the pIOL with intraocular structures.4,8-14, The original model of Artiflex I pIOL (Ophtec, Groningen, The Netherlands) launched in 2004 and then withdrawn from the market, had some of these complications due to presumed too shallow haptic angle but the newer currently available Artiflex pIOL (model 401, Ophtec, Groningen, The Netherlands) has a new configuration, the step-vaulted haptic in high range powers (−2.00 to −14.50 D).4,9-11

Herein we describe a case with acute posterior synechia formation implantation in the patient’s left eye, following bilateral simultaneous Artiflex pIOL (model 401) foldable silicone iris fixated pIOL.

Case Report

A 26-year-old man was referred for refractive surgery for high bilateral myopia (−14.0 Diopters) in both eyes. A written informed consent letter has been signed by the patient to allow any case details and any accompanying images published. Based on our hospital policy, Institutional Review Board (IRB) was not required as it was a case report.

The uncorrected distance visual acuity (UCDVA) was 2.00 logMar (Snellen 20/4000) in both eyes; the corrected distance visual acuity (CDVA) was 0.2 logMar (Snellen 20/32) with −14.00 −1.00×180 in the right eye and 0.3 logMar (Snellen 20/40) with −14.50−1.25×20 in the left eye.

The intraocular pressure before surgery was normal (14.0 mm Hg) in both eyes. Measurement of ACD between the corneal endothelium and the anterior surface of the crystalline lens, was obtained using the Orbscan II (Bausch & Lomb, Rochester, NY). In the left eye, anterior chamber depth was 3.41mm preoperation and 3.47 mm after surgery; central corneal thickness before and after surgery was 510 μm and 504 μm, respectively; and photopic pupil size (Orbscan II, Bausch & Lomb) before and after surgery was 4.35 mm and 4.38 mm, respectively. Keratometries were 44.1 @ 85 and 42.5 @ 175 in the right eye and 44.7 @ 87/43.1 @ 177 in the left eye. Preoperative corneal endothelial cells density [measured by non-contact specular microscopy (Topcon Corporation, Tokyo, Japan)] was 2533 in the right eye and 2520 in the left eye. Fundoscopy and slit-lamp examination were unremarkable.

The surgical procedure was performed bilaterally under general anesthesia in June 2016 and was uneventful. It started with paracentesis at 10 o’clock and 2 o’clock positions. The ophthalmic viscoelastic device contains sodium hyaluronate 1% was injected into the anterior chamber (AC). A 3.2 mm superior limbal tunnel incision was made on the steep meridian, and then −14.0 D Artiflex pIOL implanted to the AC. The Artiflex II pIOL was rotated into the 3 to 9 o’clock position and enclavated in the iris. An iridectomy was done at 12 o’clock in both eyes. The ophthalmic viscoelastic device was irrigated out of the AC by the main incision, and incisions stromal hydration was performed.

One day after surgery, the Artiflex (model 401) was stable in the appropriate position and iris had normal movement. The UCDVA in both eyes was 0.2 logMar (Snellen 20/32). On the third postoperative day, the patient had significant pain in the left eye and was seen in the eye emergency room at the weekend. The visual acuity was decreased to 0.4 logMar (Snellen 20/50) in the left eye. The intraocular pressure was 14.0 mm Hg, and on slit-lamp examination, the cornea was clear. However, a significant anterior chamber reaction (4+ cell and flare) was detected and therefore, anterior uveitis was diagnosed. The amount of iris tissue between the iris-claw and the iridectomy size was larger in the left eye. The diagnosis at that time was severe postoperative inflammation in the left eye, and topical steroids and mydriatic eye drops (betamethasone every one hour and tropicamide every six hours) were prescribed for the patient. On the fifth postoperative day, the right eye was quiescent with a well-centred pIOL (Figure 1). However, the left eye had a dilated atrophic iris and atonic pupil with significant posterior synechias over the inferior half of the pupil and some degrees of ectropion uvea and 3+ anterior chamber cell and flare (Figure 2). The mydriatic eye drop was discontinued. However, after intensive topical steroid application (every one hour on the day after the first postoperative visit and tapered gradually to once a day in two months), the synechias decreased but remained in the inferior part of the pupil in the next visits. Three months after surgery, the patient continued to complain of blurry vision in his left eye with UCVA of 0.5 logMar (Snellen 20/63) and the CDVA, 0.3 logMar (Snellen 20/40) with +1.00–0.75@180. One year after the operation, the left eye was quiescent, but the synechia persisted, and the iris was rather atrophic.

Figure 1

On the fifth postoperative day, the right eye was calm with a well centered phakic intraocular lens.

Figure 2

On the fifth postoperative day, the left eye had a dilated atrophic iris and atonic pupil with significant posterior synechias over the inferior half of the pupil and some degrees of ectropion uvea and pigment deposits on the phakic intraocular lens.

Discussion

Previous studies indicate that Iris-claw pIOLs appear to be an appropriate option for high myopia treatment that could be more effective than laser refractive surgery.1 For this surgery, it is mandatory to carefully perform a preoperative assessment of ocular parameters, including AC depth, iris examination, pupil size, and endothelial cell count (ECC). AC depth is vital in terms of prevention of corneal endothelial cells loss and anterior subcapsular cataract formation.5–7 The postoperative inflammatory reactions have been observed in some cases following implantation of pIOL. The pIOL positioning is essential since a tight enclavation can lead to induce postoperative refractive changes.4,15-17

Koss et al4 reported a case with posterior synechias one month after the operation and hypothesized that during surgery, too much iris tissue had been grasped, leading to a too tight enclavation of the iris-claw pIOL. They managed the patient with steroid treatment followed by re-enclavation to halt the progression of synechia progression. In our case, the enclavation was appropriate in the right eye but appeared to be too tight (including too much iris tissue) in the left eye, which in turn seemed to play a significant role in inducing postoperative inflammation and synechia formation. However, given the unsuccessful outcome of re-enclavation to release synechia in Koss et al4 report, the surgeon preferred not to re-enclavate the pIOL. It seems that once the posterior synechia occurred following increased intraocular inflammation, re-enclavation would not subside it and may even exacerbate the intraocular inflammation due to excessive iris tissue manipulation. Another difference between the two eyes of this patient is the much larger iridectomy size in the affected eye, which might cause more inflammation due to increased iris tissue manipulation.

Authors believe that treatment with corticosteroids was an excellent option in stabilizing the situation and reduce the extent of synechia. However, persistent synechia remained even one year after surgery.

We hypothesize that excessive iris tissue enclavation in the pIOLs haptics and large iridotomies may cause more intraocular inflammation and even synechia formation, and we suggest that it is prudent to avoid them during iris-claw pIOL implantation. Mydriatic eye drops should also be avoided in case of postoperative inflammation since it may lead to a persistent dilated pupil and decreased vision if synechia happens. Considering possible longstanding and even permanent vision limiting complications, bilateral pIOL implantation is not encouraged.